Validus is focused on acquiring, reformulating, and marketing prescription products in specialty therapeutic areas. Our business is based on acquisition of established products that are FDA-approved and satisfy unmet clinical needs.
John Kinney is the CEO of Validus Pharmaceuticals. His experience over the last 25 years includes roles in commercial strategy, sales and marketing, franchise management, operations, and finance. Prior to joining Validus, John held franchise head and strategic marketing positions at Sandoz, Mylan, Genentech, and Roche – leading franchise and brand teams as well as implementing strategic turnarounds in the areas of Anti-infectives, Diabetes, Anesthesia, Metabolic, Hepatitis, HIV, Influenza and Oncology. John has also been a senior leader in the management consulting practice at PwC for Life Sciences, focusing on new launches, commercial effectiveness, patient engagement, due diligence evaluation, and post merger integration. John has an MBA from NYU’s Stern School of Business, a Masters in Biology from Seton Hall University, and a BS in Chemistry from the Pennsylvania State University.
Emile Williams is Chief Operating Officer of Validus Pharmaceuticals. Emile has over 20 years of experience as a senior finance and commercial operations executive driving strategic planning, business transformation, and profit improvement across fast-paced global pharmaceutical companies. In his most recent position, Emile was Executive Vice President and Chief Commercial Officer for Shionogi. Prior to his appointment, Emile was Senior Vice President, Finance and Information Technology for Shionogi, providing financial oversight for the rapid development and commercialization of pipeline products. Prior to Shionogi, Emile held several senior finance leadership positions with Novartis Pharmaceuticals and Hoffmann-La Roche. Emile earned an M.B.A. from Loyola University in Maryland, and a B.S. in Economics & Accounting from Fourah Bay College at the University of Sierra Leone.